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Introduction
Polycystic ovary syndrome (PCOS) is a endocrine
disorder that affects 4% - 6% of females [1-3]. It is
the most common hormone-metabolic disturbance
among women of reproductive age and leading cause
of anovulatory infertility. For PCOS patients that
failed to ovulate with clomiphene citrate and follow-
ing chronic low-dose gonadotropin protocols assist-
ed reproductive techniques (ART) are proposed [4].
However, some authors indicated that obesity, inde-
pendent of insulin resistance, may be associated with
relative gonadotropin resistance [5]. Additionally,
exaggerated response to gonadotropins associated
with high risk of ovarian hyperstimulation syndrome
(OHSS) potentially complicates controlled ovarian
hyperstimulation (COH) in those patients. Excessive
response to gonadotropins may often results in high-
er estradiol (E2) level on the day of hCG adminis-
tration what can potentially affect oocyte maturity
[6] and quality [7]. A negative correlation between
BMI and number of collected oocytes in non-PCOS
and PCOS patients was also reported [8,9]. Further-
more, abnormalities of folliculogenesis and granu-
lose cell function have been observed in patients
with PCOS [10].
The higher percentage of low-quality oocytes in
PCOS may promote lower fertilization rates and
embryos of poorer quality that have been reported in
PCOS patients compared with control women under-
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Abstract: Introduction: Polycystic ovarian syndrome (PCOS) is a hormonal and metabolic disorder which poses problems
with controlled ovarian stimulation (COH). It has been also postulated that PCOS patients have oocytes and embryos with
poorer quality which affects IVF results. Aim: To verify IVF outcome in non-obese patients with PCOS. Materials and meth-
ods: IVF results of 71 non-obese PCOS patients with 243 non-obese non-POCS patients, regardless of stimulation protocol,
from years 2004-2006 were compared. Results: Biotechnological results of PCOS patients in opposition to non-PCOS
patients were respectively as follows: higher average number (10.19 vs. 7.61; p=0.001) and percentage (82.34% vs. 76.25%;
p=0.025) of retrieved mature M2 oocytes; similar (77.01% vs. 76.75%; p=0.835) fertilization rate with higher average num-
ber of embryos (7.633 vs. 5.650 p=0.003); higher average number (4.830 vs. 3.304; p=0.001) and percentage (65.66% vs.
60.57%; p=0.006) of embryos with optimal Z1 and Z2 pronuclei pattern according to Scott; higher average number of class
A embryos (3.57 vs. 2.34; p=0.001). Similar number of embryos were transferred in both groups (2.408 vs. 2.485, p=0.552).
Clinical results in PCOS and non-PCOS patients were as follows: similar stimulation duration (10.53 days vs. 10.31 days;
p=0.639) with significant less gonadotropin total usage (1866.54 IU vs. 2276.18 IU; p=0.001). Also clinical pregnancy per
transfer (57.75% vs. 41.98%; p=0.021) and delivery per transfer (45.07% vs. 32.51%; p=0.066) were more often in PCOS
patients with comparable miscarriages (12,68% vs. 6,58%; p=0.131) and ectopic pregnancy (0.00% vs. 2.06%; p=0.591)
rates, respectively. Conclusion: PCOS in non-obese patients is linked with good biotechnological and clinical IVF outcome. 
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going ART [7]. However, others noted comparable
general implantation and pregnancy rates in PCOS
patients when compared to controls [11]. 
The aim of this study was to verify oocyte and
embryo quality as well as clinical outcome in PCOS
non-obese patients undergoing IVF. To avoid influence
of obesity on general in vitro fertilization (IVF) out-
come we decided to exclude obese patients in our
study.
Materials and methods 
Patients. A total of 314 infertile women, between 23 and 44 years
of age, who underwent intracytoplasmic sperm injection (ICSI)
treatment in the Department of Reproductive Medicine and Gyne-
cology, Pomeranian University of Medicine in Szczecin in years
2004-2006 were retrospectively analyzed. General inclusion crite-
ria for all study participants included: body mass index (BMI) <28
kg/m2. Additionally, for PCOS patients: meeting of 2003 Rotter-
dam PCOS criteria. General exclusion criteria for all study partic-
ipants included: ≥2 miscarriages, ≥3 unsuccessful IVF cycles,
anatomical abnormalities of the uterus on laparoscopy or hys-
teroscopy. Group I consisted of 243 non-PCOS patients with mean
age of 32.44 ± 4.17 (SD) years. Group II included 71 PCOS
patients with a mean age of 30.77 ± 3.63 (SD) years. The clinical
characteristics of the patients in both examined groups are shown
in Table 1.
Protocol for controlled ovarian hyperstimulation. To synchro-
nize menstrual cycle before starting IVF patients were receiving
oral monophasic contraceptives pills (Cilest; Janssen-Cilag, Bel-
gium) for a month. In both protocols, only two clinicians and two
embryologists were involved in the study. GnRH antagonist and
agonists protocol were used in both studied groups. During ovari-
an hyperstimulation human menopausal gonadotropin hMG
(Menopur, Ferring Pharmaceuticals, Holland) or recombinant
human FSH (Gonal F; Serono Pharma, Switzerland) were used.
PCOS patients were stimulated only with recombinant human FSH
(recFSH, Gonal F; Serono Pharma, Switzerland) as it was also the
case in GnRH antagonist protokols. 
GnRH antagonist protocol. From the 2nd day of the cycle women
were given regular daily recFSH subcutaneous injections (usually
between 18.00 and 20.00 hours). With a starting dose of a 150IU
per day which was adjusted individually depending on patients
response measured by transvaginal ultrasonography and the levels
of E2. Ultrasound and E2 levels monitoring started from the 7th
day of the cycle (6th day of COH) after 5 doses of recFSH and was
continued every second day and the day of hCG administration. A
GnRH antagonist - cetrorelix (Cetrotide; Merck Serono, Germany)
was administered subcutaneously between 8.00 and 12.00 hours
when at least two ovarian follicles reached 14mm in diameter. The
protocol consisted of daily Cetrotide 0,25 mg subcutaneous injec-
tions, average 4, until the criteria for recombinant human chorion-
ic gonadotropin (hCG) administration were met. For final oocyte
maturation, when the dominant follicle reached ≥18mm with the
following two ≥16mm and E2 levels between 1000-4000 pg/mL,
an intramuscular (Pregnyl; Organon, Holland) injection of 10.000
IU hCG or subcutaneous (Ovitrelle; Merck Serono, France) injec-
tion of 250 μg hCG was given.
GnRH agonist protocol. During oral contraception (OC) on days
16-18 of the preceding cycle, after transvaginal ultrasonographic
screening of ovaries, an intramuscular injection of GnRH agonist
triptorelin (Diphereline SR 3.75; Boufor Ibsen Pharma, France)
was given. After 14 days, if the level of LH was <2 mIU/mL and
E2 <50 pg/mL the administration of gonadotropins commenced.
Women were given regular daily recFSH or hMG subcutaneous
injections (usually between 18.00 and 20.00 hours). Also in this
protocol starting dose was 150 IU per day, which was adjusted
individually, depending on patients response. Similarly, ultrasound
and E2 level monitoring started from the 7th day of the cycle (6th
day of COH) after 5 doses of gonadotropins and was continued
every second day and the day of hCG administration. The GnRH
antagonist protocol final oocyte maturation was induced by an
intramuscular (Pregnyl) injection of 10.000 IU hCG or subcuta-
neous (Ovitrelle) injection of 250 μg hCG when the dominant fol-
licle reached ≥18 mm with the following two ≥16 mm and E2 level
was between 1000-4000 pg/mL. 
Oocytes retrieval. Oocytes were retrieved with transvaginal ultra-
sound guided aspiration needle (OPS Single lumen: without tap;
Laboratoire C.C.D, France) 36 hours after hCG administration to a
collection tubes containing HEPES-buffered medium (FertiCult
Flushing medium, FertiPro, Belgium), washed, and then cultured
in ISM1 medium (Medicult, Denmark). Before ICSI, a 10%
hyaluronidase solution (Hyaluronidase solution in Flushing Medi-
um, FertiPro, Belgium) dose was used to remove cumulus cells.
After that, oocytes were washed in flushing medium (FertiCult
Flushing medium, FertiPro, Belgium) until the ICSI procedure. 
Embryological assessment. Retrieved oocytes were classified in
metaphase II (M2) as mature and in metaphase I (M1) or germinal
vesicle stage (GV) as immature. Fertilizations were checked dur-
ing routine non-invasive examination 16-18 hours after ICSI
[12,13]. Embryo grading was assessed on the pronuclear stage
according to the Scott criteria and on the day of the Embryo trans-
fer (ET) according to the internal laboratory cumulative embryo
score standards [14,15]. We also distinguished A class embryos on
the third day of the culture defined as an embryo with ≥8 symmet-
rical, non-fragmented blastomers. Decision on number of trans-
ferred embryos was taken according to 2006 ASRM embryo-trans-
fer guidelines [16]. Embryos were transfer to uterine cavity was in
catheter (Frydman Soft 4.5 with guide, Laboratoire C.C.D.,
France) 72 hours after ICSI.
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Table 1. Clinical characteristics of study participants in both studied groups expressed as means ±SD; NS - not significant; a - Mann-
Whitney test. 
Luteal support. Luteal phase support included simultaneous oral
30 mg/day of dydrogestreon (Duphaston; Solvay Pharma, Bel-
gium) and intravaginal 150 mg/day of progesterone (Luteina;
Adamed, Poland). 
Pregnancy was confirmed by pregnancy test 14 days after ET
and by vaginal ultrasound scan at 5 weeks gestation. Subsequently
after 11th week of gestation. Biochemical gestation was not taken
into consideration at any stage of the trial. 
Outcome measures.
Biotechnological endpoints: 
• number and percentage of retrieved matured oocytes (M2),
defined as proportion of metaphase II (M2) to total number of
retrieved oocytes; 
• fertilization rate defined as proportion of two pronuclei oocytes
to number of injected oocytes; 
• analysis of quality of all zygotes on 1st day of the culture and
of transferred embryos on 3rd day of culture  
Clinical endpoints: 
• number of days of gonadotropin treatment; 
• gonadotropin use; 
• clinical pregnancy per attempt, defined as an ongoing preg-
nancy at 12 weeks of gestation; 
• delivery per attempt, defined as proportion of deliveries to
number of patients in group 
• multiple pregnancy per attempt, 
• miscarriages per attempt.
Statistics. Chi-square test or Fisher's exact test for 2×2 tables were
used to analyze statistical significance for qualitative variables.
Non-normally distributed variables were analyzed by non-para-
metric Mann-Whitney test. P value <0,05 was considered as sig-
nificant. All calculations were performed using Statistica for Win-
dows 7.1 (StatSoft Inc., Tulsa;USA). 
Ethical issues. All women signed informed consent before study
participation according to local ethical committee at Pomeranian
University of Medicine.
Results
Three hundred fourteen enrolled in the study patients
underwent embryo transfer (ET). The comparison of
biotechnological outcome measures in non-PCOS and
PCOS patients are shown in Table 2.
Total number of retrieved oocytes (p=0.002), num-
ber (p=0.003) and percentage (p=0.034) of immature
GV oocytes retrieved as well as number (p=0.014) and
percentage (p=0.060) of immature M1 oocytes
retrieved as well as number (p=0.001) and percentage
(p=0.02) of mature oocyte (M2) and number of fertil-
ized oocytes (p=0.001) were significantly lower in
non-PCOS patients comparing with PCOS patients.
However, fertilization rate was similar in both studied
groups (p=0.835). 
Although we noticed significantly lower number of
zygotes with optimal pronuclear morphology classi-
fied as Z1 (p=0.016) and Z2 (p=0.001) as well as Z1
and Z2 together (p=0.001) in non-PCOS patients, the
percentage of mentioned pronuclear patterns Z1
(p=0.459), Z2 (p=0.137), both Z1 and Z2 (p=0.237)
was similar in both groups. Nevertheless, zygotes with
optimal pronuclear morphology dominated in a cohort
of fertilized oocytes in both studied groups. There
were no significant differences in number (p=0.09)
and percentage (p=0.660) of zygotes with suboptimal
pronuclear morphology described as Z3 and number
(p=0.441) and percentage (p=0.228) of zygotes with
non-optimal described as Z4. 
Embryos qualified to the ET originated primarily
from Z1 or Z2 zygotes. However, significantly lower
number (p=0.024) and percentage (p=0.006) of
embryos which had a history of optimal pronuclear
Z1+Z2 pattern and considerably higher number
(p=0.014) and percentage (p=0.012) of embryos which
had suboptimal Z3 pattern were transferred in non-
PCOS women. We observed significantly lower num-
ber of high quality class A embryos in a cohort of all
embryos of non-PCOS patients (p=0.001). Similar
number of embryos were transferred in both groups
(p=0.552) with comparable mean number of blas-
tomers per transfer (p=0.176). Needless to say, the
biotechnological data did not differ in relation to stim-
ulation protocol within the studied groups of patients
(data not included).
The results originating from clinical data are shown
in Table 3. The number of stimulation days did not dif-
fer (p=0.639) but total gonadotropin dose was signifi-
cantly higher (p=0.001) in a non-PCOS group. Signif-
icantly higher (p=0.001) serum E2 level on the day of
hCG was observed in PCOS group.
Pregnancy rate per attempt was significantly lower
(p=0.021) but the delivery rate per attempt did not dif-
fer statistically (p=0.066) in non-PCOS vs. PCOS
group. There were no statistical differences in multiple
pregnancy (p=0.179), miscarriage (p=0.131) and
ectopic pregnancy (p=0.591) rates.
Discussion
There are many studies assessing IVF outcome among
PCOS patients. Generally, where IVF or ICSI have
been performed for PCOS-associated infertility, the
outcome is similar to other forms of infertility [17].
When comparing PCOS patients to controls, more fol-
licles are produced and more oocytes are collected
with a lower dose of total gonadotropins, general
implantation and pregnancy rates are noted to be com-
parable [8,18]. Nevertheless, studies with comprehen-
sive assessment of oocytes and embryos, especially in
PCOS women, are lacking. 
Available trials concentrates mainly on oocyte
quality and clinical outcome such as fertilization,
implantation and pregnancy rate. Numerous authors
reported poorer quality of collected oocytes with lower
fertilization capacity in PCOS cycles [6,19,20]. Lud-
wig et al. [18] observed among PCOS women who
underwent ICSI similar rate of metaphase II oocytes,
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Table 2. Comparison of biotechnological outcome measures in non-PCOS and PCOS patients. Values are expressed as means ±SD; NS
- not significant; Z1+Z2 - optimal pronuclei pattern. a - Mann-Whitney test. 
fertilization and embryo development rates in compar-
ison to controls. Heijnen et al. [21], in a meta-analysis
of nine studies which compared conventional IVF out-
comes in PCOS patients with matched controls, report-
ed significantly more oocytes per oocyte retrieval
obtained in PCOS group comparing with controls but
higher fertilization rate in the control group which
resulted in an equal number of fertilized oocytes in
both studied groups. In the current study PCOS
patients comparing to non-PCOS had more retrieved
oocytes. Although we observed higher number of
immature (GV and M1) oocytes in PCOS patients, we
also noticed higher number of mature (M2) oocytes,
what with comparable fertilization rate in both studied
groups resulted in higher mean number of fertilized
oocytes comparing with non-PCOS patients. We also
observed that despite significantly lower FSH con-
sumption, serum E2 level on the day of hCG adminis-
tration was higher in PCOS patients. But that did not
affect M2 oocyte quality, in terms of fertilization and
embryo development in PCOS patients. Similarly, in
Esinler et al. [22] study where PCOS patients had sig-
nificantly higher E2 level on hCG day and higher num-
ber of metaphase II oocytes comparing with non-
PCOS patients. 
Some authors focused on abnormalities of follicu-
logenesis and granulose cell function in patients with
PCOS [10]. In one study, anomalous expression of
important oocyte-derived factor - growth differentia-
tion factor 9 (GDF-9), which plays significant role in
early follicular development and appear to have a part
in controlling cumulus expansion in the preovulatory
follicle, was found in oocytes from PCOS patients
[23]. Also abnormal endocrine in vivo milieu, expo-
sure to increased levels of LH and insulin has been
postulated to contribute abnormal granulose cell func-
tion [10]. Laven et al. [24] suggests that normal inhib-
in B level produced by pre-antral and small antral fol-
licles founded in PCOS patients is probably responsi-
ble for not increased number of healthy non-atretic fol-
licles. Sengoku et al. [25] compared the chromosomal
normality of unfertilized oocytes from PCOS patients
vs. patients with tubal infertility and observed reduced
fertilization rate but there was no differences in oocyte
aneuploidy rates between two groups. Authors come to
a conclusion that the reduced fertilization rate is not
caused by chromosomal aberrations or immaturity of
oocytes collected from PCOS patients [25]. On the
other hand, Wood et al. reported recently molecular
abnormalities in PCOS oocytes which could account
for reduced fecundity [26].
Non-invasive methods of embryo evaluation has
been widely employ to help assess embryos without
damage [15]. We found the zygote scoring by Scott
[14] to be simple and useful as a predictive factor for
further development of the embryos and for pregnancy
[27]. In current study zygotes with optimal (Z1+Z2)
pronuclear morphology dominated in comparison to
sub and non-optimal configuration of pronuclei in both
studied groups. Nevertheless, patients with PCOS had
statistically more zygotes with optimal pronuclear pat-
tern than non-PCOS patients. In consequence, statisti-
cally more embryos with most favorable pronuclear
morphology were available to transfer on 3rd day of
the culture in PCOS group. We identify significantly
more class A embryos among all embryos in PCOS
group. However, regardless mean number of blas-
tomers in transferred embryo, symmetry and fragmen-
tation of transferred embryos was similar. Good quali-
ty of embryos in PCOS patients could be related to our
strict inclusion criteria. The risk of metabolical distur-
bances and its negative influence of the oocyte and fur-
ther and the embryo quality in this group is relatively
lower in compare to obese PCOS patient [8,9]. 
Heijnen et al. [21] reported significantly longer
duration of stimulation and no significant difference in
the amount of gonadotropins used in PCOS group
compared with controls. Conversely, in our study the
number of stimulation days did not differ between both
studied groups but total gonadotropin dose was signif-
icantly higher in a non-PCOS group comparing to
PCOS group. This could be associated with homogeny
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Table 3. Comparison of clinical outcome measures in non-PCOS and PCOS patients. Where appropriate values are means (±SD); NS -
not significant; E2 - estradiol; a - Mann-Whitney test; b - Fisher exact test.
of PCOS group in our study comparing with Heijnen et
al. analysis which included all PCOS patients regardless
of BMI. Maheshwari et al. [28] as well as Fedorcsak et
al. [9] reported that obese patient need more
gonadotropins during COH comparing to non-obese.
In current study, similarly to Esinler et al. [22],
pregnancy rate per attempt was significantly higher in
PCOS group than in non-PCOS group and delivery
rate per attempt was higher in PCOS group, but prob-
ably because of little group did not differ statistically.
This results may indicate that excluding obesity
improved oocyte and embryo quality and in conse-
quence overall outcome. Also analogously to Esinler et
al. [22] we did not observe statistical differences com-
paring non-PCOS patients and PCOS patients in mul-
tiple pregnancy rate. Heijnen et al. [21] did not
observed significant difference for pregnancy attempt,
delivery per attempt and the number of miscarriage
between PCOS and non-PCOS patients. Miscarriages
rate among PCOS patients in our study were also sim-
ilar in both studied groups. Also Esinler et al. [22]
reported comparable miscarriage rate in PCOS and
non-PCOS group.
We noted that patients with PCOS may have more
favorable ICSI outcome compared to non-PCOS
patients. Our study shows, that the higher number of
available embryos increases the chances of more good
quality embryos development and allows to transfer
top-quality embryos in the PCOS group which may
result in significantly higher pregnancy rates and high-
er delivery rates in the PCOS group comparing to the
non-PCOS patients. Concluding, the presence of
PCOS in non-obese patient may be a favorable prog-
nostic factor before considering IVF. 
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